A Comparative Analysis of Speech Perception Between Cochlear Implant Patients and DFNB9 Patients Receiving Gene Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-06

Study Completion Date

2026-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cohort study aims to explore the trends and differences in multidimensional perceptual levels of patients after cochlear implants or gene therapy, as well as to comprehensively assess the efficacy of gene therapy for congenital deafness, thus providing a reference for making a well-rounded postoperative rehabilitation protocol for gene therapy patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perceptual Evaluation and Rehabilitation System Development for Congenital Hearing Loss

NCT07024524

Congenital Hearing Loss Gene Therapy Speech Perception +2 more

RECRUITING NA

Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces

NCT05867173

Deafness

RECRUITING NA

Improved Speech Recognition Performance in Noise by Encoding Binaural Spatial Cues to the Cochlear Implant User.

NCT04357704

Hearing Loss, Cochlear

WITHDRAWN NA

Evaluating a Deep Neural Noise-Reduction Algorithm for Hearing Aids

NCT07287774

Hearing Loss, Cochlear

RECRUITING NA

Brain Mechanism and Outcome of Surgical Intervention of Conductive Hearing Loss.

NCT06535282

Conductive Hearing Loss Tinnitus Surgery

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cochlear implant patients exhibit improved speech perception in quiet environments after surgery, but their music perception and speech perception under noise are still unsatisfactory. Gene therapy is a novel and promising treatment for congenital hearing loss to recover natural hearing sensations. To date, for patients with congenital deafness, there has been no study on their ability to perceive and understand sounds, such as speech perception in noise, music and directional perception, after hearing recovery owing to gene therapy. In addition, the difference between the two treatments in those perceptual levels postoperatively remains unknown.

Therefore, the investigators designed a single-center cohort study. Based on the intervention method, congenital deafness patients are divided into two groups: the cochlear implant group and the gene therapy group. In the present study, a full-scale evaluation of the two groups will be conducted. The battery encompasses auditory speech perception, cognition, psychological status, and auditory cortex development. A comparative analysis will be conducted to examine multidimensional differences between the two groups, shedding light on the divergent outcomes of gene therapy and cochlear implants for patients with congenital deafness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hearing Loss Genetic Disease Speech Perception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gene Therapy Group

The study will recruit gene therapy patients who are definitely diagnosed with autosomal recessive deafness 9 (DFNB9).

No interventions assigned to this group

Cochlear Implant Group

The study will recruit cochlear implant patients with congenital deafness.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with congenital hearing loss with hearing thresholds ≥65 dB receive either gene therapy (previously received gene therapy and standardized postoperative rehabilitation and follow-up or plan to receive gene therapy), or cochlear implant surgery. Healthy participants with bilateral hearing thresholds within the normal range (≤20 dB), generally matched to the gene therapy group and the cochlear implant group by age and sex.
* Age ≥ 6 months old, regardless of gender.
* Mandarin Chinese as the native language.
* Participants and their guardians must provide informed consent before the trial, voluntarily sign a written consent form, and commit to follow-up at specified time points.
* Capable of effective communication with researchers under the guardian's assistance and willing to cooperate and comply with the researchers' requirements.
* The participant's guardians should have a correct understanding of the trial and appropriate expectations regarding potential benefits.

Exclusion Criteria

* Presence of other otological disorders that may interfere with the surgical outcome or interpretation of study endpoints, such as middle/inner ear dysplasia or malformations that affected the therapeutic effect revealed in CT/MRI scans within 3 months, vestibular-cochlear nerve abnormalities, acute/chronic otitis media, Meniere's disease, etc.
* Presence of other severe congenital diseases.
* Presence of severe systemic diseases or in the acute onset of diseases, such as pulmonary tuberculosis, active hepatitis B or C infection, active herpes zoster infection, pancreatitis, renal insufficiency, etc.
* Individuals with low immunity, a history of immune deficiency or organ transplantation.
* Individuals with a history of neurological or mental disorders, such as epilepsy or dementia.
* Patients with contraindications for surgery or anesthesia assessed by a surgeon, anesthetist, or designated personnel, such as cardiovascular or cerebrovascular events in the past 6 months, allergies to the planned medications, etc.
* Gene therapy group: gene therapy did not restore hearing; Cochlear implant group: presence of hereditary syndromic deafness or other conditions that seriously affect the efficacy evaluation.
* Any other conditions for which the investigators consider the subject unsuitable for participation in this clinical study.

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yilai Shu, M.D. & Ph.D.

Role: STUDY_CHAIR

Eye & ENT Hospital of Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.